BACKGROUND AND OBJECTIVES: Current assays and tests that are used to determine the degree of immunosuppression in renal transplant recipients are suboptimal. The ImmuKnow assay (Cylex), a measure of intracellular CD4+ T cell ATP release proposed as a means to quantify cell-mediated immunity in transplant recipients, could be considered as a potential tool to identify patients at risk for opportunistic infections (OI) or acute rejection (AR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively analyzed 1330 ImmuKnow assay values in 583 renal transplant recipients at a single center from 2004 to 2009 and correlated these values with episodes of OI and AR in the subsequent 90 days. Assay values were compared with a control population matched for age, gender, and time post-transplantation. RESULTS: In patients with OI (n=94), there were no differences in prior mean assay values compared with matched controls (386 versus 417 ng/ml, P=0.24). In 47 patients with AR, again no differences were detected in prior assay results (390 versus 432 ng/ml, P=0.25) when compared with controls. "Low" values (≤225 ng/ml) lacked sensitivity and specificity as a predictive test for subsequent OI, as did "strong" (≥525 ng/ml) values as a predictive test for subsequent AR. CONCLUSIONS: Our results fail to show an association between single time point ImmuKnow assay values and the subsequent development of an adverse event in the subsequent 90 days. The optimal use of the ImmuKnow assay in kidney transplantation has yet to be determined.
BACKGROUND AND OBJECTIVES: Current assays and tests that are used to determine the degree of immunosuppression in renal transplant recipients are suboptimal. The ImmuKnow assay (Cylex), a measure of intracellular CD4+ T cell ATP release proposed as a means to quantify cell-mediated immunity in transplant recipients, could be considered as a potential tool to identify patients at risk for opportunistic infections (OI) or acute rejection (AR). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively analyzed 1330 ImmuKnow assay values in 583 renal transplant recipients at a single center from 2004 to 2009 and correlated these values with episodes of OI and AR in the subsequent 90 days. Assay values were compared with a control population matched for age, gender, and time post-transplantation. RESULTS: In patients with OI (n=94), there were no differences in prior mean assay values compared with matched controls (386 versus 417 ng/ml, P=0.24). In 47 patients with AR, again no differences were detected in prior assay results (390 versus 432 ng/ml, P=0.25) when compared with controls. "Low" values (≤225 ng/ml) lacked sensitivity and specificity as a predictive test for subsequent OI, as did "strong" (≥525 ng/ml) values as a predictive test for subsequent AR. CONCLUSIONS: Our results fail to show an association between single time point ImmuKnow assay values and the subsequent development of an adverse event in the subsequent 90 days. The optimal use of the ImmuKnow assay in kidney transplantation has yet to be determined.
Authors: Ajda T Rowshani; Frederike J Bemelman; Ester M M van Leeuwen; René A W van Lier; Ineke J M ten Berge Journal: Transplantation Date: 2005-02-27 Impact factor: 4.939
Authors: R Cadillo-Chávez; Sally de Echegaray; E A Santiago-Delpín; A T Rodríguez-Trinidad; B Camacho-Carrazo; T Alfaro; M Saavedra-Pozo; L Carrasquillo; Z A González-Caraballo; L A Morales-Otero Journal: Transplant Proc Date: 2006-04 Impact factor: 1.066
Authors: Richard J Kowalski; Diane R Post; Roslyn B Mannon; Anthony Sebastian; Harlan I Wright; Gary Sigle; James Burdick; Kareem Abu Elmagd; Adriana Zeevi; Mayra Lopez-Cepero; John A Daller; H Albin Gritsch; Elaine F Reed; Johann Jonsson; Douglas Hawkins; Judith A Britz Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: Richard Kowalski; Diane Post; Mary C Schneider; Judith Britz; Judy Thomas; Mark Deierhoi; Andrew Lobashevsky; Robert Redfield; Eugene Schweitzer; Alonso Heredia; Elise Reardon; Charles Davis; Carol Bentlejewski; John Fung; Ron Shapiro; Adriana Zeevi Journal: Clin Transplant Date: 2003-04 Impact factor: 2.863
Authors: Yiping Chen; Jennifer Trofe; Jennifer Gordon; Renaud A Du Pasquier; Prabir Roy-Chaudhury; Marcelo J Kuroda; E Steve Woodle; Kamel Khalili; Igor J Koralnik Journal: J Virol Date: 2006-04 Impact factor: 5.103
Authors: I Pérez-Flores; A Sánchez-Fructuoso; J L Santiago; M Fernández-Arquero; N Calvo; E Gómez de la Concha; A Barrientos Journal: Transplant Proc Date: 2009 Jul-Aug Impact factor: 1.066
Authors: Pietro E Cippà; Marc Schiesser; Henrik Ekberg; Teun van Gelder; Nicolas J Mueller; Claude A Cao; Thomas Fehr; Corrado Bernasconi Journal: Clin J Am Soc Nephrol Date: 2015-10-01 Impact factor: 8.237
Authors: Benjamin L Laskin; Jing Jiao; H Jorge Baluarte; Sandra Amaral; Susan L Furth; Tatiana Akimova; Wayne W Hancock; Matthew H Levine; Peter P Reese; Ulf H Beier Journal: Transplant Direct Date: 2017-07-19